New preclinical and translational imaging work focuses on improving how clinicians track and potentially treat solid tumors. A dual-target radioligand, INN02, delivered both enhanced tumor imaging and therapeutic activity in early testing, binding two tumor microenvironment hallmarks at once according to a Journal of Translational Medicine study. In parallel, other findings in the dataset point to evolving approaches for targeting difficult-to-treat cancers—ranging from imaging tracers adapted to different malignancies to refinements in how immune pressure is applied in the tumor microenvironment. For developers, the emphasis on multi-parameter tumor characterization reflects a growing push to connect pharmacology with real-time imaging readouts, enabling earlier go/no-go decisions and more precise patient selection.